Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HypoSalix is an electrolyte-based saliva substitute indicated for the symptomatic relief of xerostomia (dry mouth). Developed by Parnell Pharmaceuticals, the product is formulated as an aqueous solution containing essential electrolytes—including sodium, potassium, calcium, magnesium, chloride, and phosphate—at concentrations that mimic the ionic strength and composition of natural human saliva. It functions primarily as a lubricant and moisturizing agent for the oral mucosa, alleviating discomfort associated with reduced salivary flow. Xerostomia often results from conditions such as Sjogren's syndrome, side effects of medications (e.g., antidepressants, antihistamines), or as a complication of head and neck radiation therapy. HypoSalix is typically administered as an oral spray to provide immediate, temporary relief of dryness and to facilitate oral functions such as speaking and swallowing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HypoSalix.